VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the BMO Capital Markets Prescriptions for Success...
Read More
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses...
Read More
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on June 13, 2019 (the "Meeting"). The...
Read More
Well tolerated at all doses with no safety signals Three patients in high dose (10 µg) cohort showed evidence of stable disease by MRI 10 μg dose selected for Part B of the study, which is expected to initiate enrollment...
Read More
All four lead pipeline programs progressing towards expected clinical milestones in 2019 Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine, expected mid-year 2019 Expanded Part A data from GBM Phase...
Read More
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBM Expanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at ASCO Conference call and webcast Thursday,...
Read More
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, is pleased to announce the appointment of Vlad Popovic, M.D., as Vice President, Clinical Development and Medical Affairs, reporting into Francisco Diaz-Mitoma, M.D.,...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Joanne Cordeiro to its Board of Directors. Ms. Cordeiro most recently served as Chief Human Resources Officer and Executive...
Read More
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccine In all three studies, seroprotection rates of more than 98% were achieved after two vaccinations of Sci-B-Vac® VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) (“the...
Read More